Please note that eDoc will be permanently shut down in the first quarter of 2021!      Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für experimentelle Medizin     Collection: Clinical Neuroscience     Display Documents



  history
ID: 292194.0, MPI für experimentelle Medizin / Clinical Neuroscience
The brain erythropoietin system and its potential for therapeutic exploitation in brain disease
Authors:Hasselblatt, Martin; Ehrenreich, Hannelore; Sirén, Anna-Leena
Language:English
Date of Publication (YYYY-MM-DD):2006-04
Title of Journal:Journal of Neurosurgical Anesthesiology
Journal Abbrev.:J. Neurosurg. Anesth.
Volume:18
Issue / Number:2
Start Page:132
End Page:138
Review Status:Peer-review
Audience:Experts Only
Abstract / Description:The discovery of the broad neuroprotective potential of erythropoietin (EPO), an endogenous hematopoietic growth factor, has opened new therapeutic avenues in the treatment of brain diseases. EPO expression in the brain is induced by hypoxia. Practically all brain cells are capable of production and release of EPO and expression of its receptor. EPO exerts Multifaceted protective effects on brain cells. It protects neuronal cells from noxious stimuli Such as hypoxia, excess glutamate, serum deprivation or kainic acid exposure in vitro by targeting a variety of mechanisms and involves neuronal, glial and endothelial cell functions. In rodent models of ischemic stroke, EPO reduces infarct volume and improves functional outcome, but beneficial effects have also been observed in animal models of subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, and spinal cord injury. EPO has a convenient therapeutic window upon ischemic stroke and favorable pharmacokinetics. Results from first therapeutic trials in humans are promising, but will need to be validated in larger trials. The safety profile and effectiveness of EPO in a wide variety of neurologic disease models make EPO a candidate compound for a potential first-line therapeutic for neurologic emergencies.
Free Keywords:EPO; neuroprotection; clinical; experimental RECOMBINANT-HUMAN-ERYTHROPOIETIN; HYPOXIA-INDUCIBLE FACTOR; PERMANENT CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; MOUSE-BRAIN; SPINAL-CORD; SUBARACHNOID HEMORRHAGE; ENHANCES NEUROGENESIS; EXPRESSION PATTERNS
External Publication Status:published
Document Type:Article
Communicated by:Hannelore Ehrenreich
Affiliations:MPI für experimentelle Medizin/Clinical neuroscience
External Affiliations:Institute of Neuropathology, University Hospital Münster, Münster; Section of Experimental Neurosurgery, Dept. of Neurosurgery, University of Würzburg, Würzburg, Germany;
Identifiers:ISSN:0898-4921 [ID No:1]
ISI:000237009800007 [ID No:2]
ISI:000237009800007 [ID No:3]
Full Text:
Sorry, no privileges
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.